- Home
- REGN vs COF Comparison
REGN vs COF Comparison
Compare REGN & COF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- COF
- Stock Information
- Founded
- REGN 1988
- COF 1988
- Country
- REGN United States
- COF United States
- Employees
- REGN N/A
- COF N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- COF Major Banks
- Sector
- REGN Health Care
- COF Finance
- Exchange
- REGN Nasdaq
- COF Nasdaq
- Market Cap
- REGN 63.4B
- COF 58.3B
- IPO Year
- REGN 1991
- COF 1994
- Fundamental
- Price
- REGN $563.16
- COF $162.77
- Analyst Decision
- REGN Buy
- COF Buy
- Analyst Count
- REGN 23
- COF 15
- Target Price
- REGN $971.57
- COF $204.36
- AVG Volume (30 Days)
- REGN 1.1M
- COF 5.4M
- Earning Date
- REGN 04-29-2025
- COF 04-22-2025
- Dividend Yield
- REGN 0.16%
- COF 1.50%
- EPS Growth
- REGN 10.27
- COF N/A
- EPS
- REGN 38.34
- COF 11.59
- Revenue
- REGN $14,202,000,000.00
- COF $27,396,000,000.00
- Revenue This Year
- REGN $4.06
- COF $52.11
- Revenue Next Year
- REGN $6.54
- COF $5.01
- P/E Ratio
- REGN $14.69
- COF $14.06
- Revenue Growth
- REGN 8.27
- COF 3.93
- 52 Week Low
- REGN $525.99
- COF $128.23
- 52 Week High
- REGN $1,211.20
- COF $210.67
- Technical
- Relative Strength Index (RSI)
- REGN 37.15
- COF 44.99
- Support Level
- REGN $544.50
- COF $157.89
- Resistance Level
- REGN $575.20
- COF $166.93
- Average True Range (ATR)
- REGN 28.44
- COF 11.20
- MACD
- REGN -1.59
- COF 0.18
- Stochastic Oscillator
- REGN 32.25
- COF 47.58
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About COF Capital One Financial Corporation
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.